Reaffirmed: Abeona Therapeutics (NASDAQ:ABEO) Buy Rating Reaffirmed by Cantor Fitzgerald; $36.0000 Target in Place

May 17, 2018 - By reb123z

Abeona Therapeutics Inc. (NASDAQ:ABEO) Logo

Abeona Therapeutics (NASDAQ:ABEO) Rating Reaffirmed

Recently, In analysts report revealed to clients and investors on 15 May, Abeona Therapeutics (NASDAQ:ABEO) shares have had their Buy Rating reiterated by equity research analysts at Cantor Fitzgerald, who currently has a $36.0000 target on firm. This target by Cantor Fitzgerald would indicate the possibile upside of 71.43 % from the current stock price.

Abeona Therapeutics Inc. (NASDAQ:ABEO) Ratings Coverage

Among 4 analysts covering Abeona Therapeutics (NASDAQ:ABEO), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Abeona Therapeutics has $36.0 highest and $26.0 lowest target. $30’s average target is 42.86% above currents $21 stock price. Abeona Therapeutics had 14 analyst reports since November 21, 2017 according to SRatingsIntel. The stock has “Buy” rating by H.C. Wainwright on Monday, May 14. The stock has “Buy” rating by RBC Capital Markets on Tuesday, January 23. H.C. Wainwright maintained it with “Buy” rating and $30.0 target in Thursday, February 1 report. The firm has “Buy” rating given on Wednesday, February 7 by Cantor Fitzgerald. H.C. Wainwright maintained Abeona Therapeutics Inc. (NASDAQ:ABEO) rating on Wednesday, November 22. H.C. Wainwright has “Buy” rating and $30.0 target. The stock of Abeona Therapeutics Inc. (NASDAQ:ABEO) earned “Buy” rating by H.C. Wainwright on Thursday, May 3. The rating was maintained by H.C. Wainwright on Thursday, April 12 with “Buy”. H.C. Wainwright maintained the shares of ABEO in report on Thursday, February 8 with “Buy” rating. The rating was maintained by H.C. Wainwright with “Buy” on Thursday, January 4. The stock of Abeona Therapeutics Inc. (NASDAQ:ABEO) has “Buy” rating given on Tuesday, March 20 by Cantor Fitzgerald.

The stock increased 2.44% or $0.5 during the last trading session, reaching $21. About 780,550 shares traded. Abeona Therapeutics Inc. (NASDAQ:ABEO) has risen 188.66% since May 17, 2017 and is uptrending. It has outperformed by 177.11% the S&P500.

Analysts await Abeona Therapeutics Inc. (NASDAQ:ABEO) to report earnings on August, 21. They expect $-0.20 EPS, up 4.76 % or $0.01 from last year’s $-0.21 per share. After $-0.18 actual EPS reported by Abeona Therapeutics Inc. for the previous quarter, Wall Street now forecasts 11.11 % negative EPS growth.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy and plasma products for severe and life-threatening rare diseases. The company has market cap of $993.41 million. The companyÂ’s lead programs are ABO-101, an adeno-associated virus based gene therapies for Sanfilippo syndrome type B; and ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A. It currently has negative earnings. It is also developing EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); EB-201 for for epidermolysis bullosa (EB); ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; ABO-301, an AAV gene therapy for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9 gene editing approach to gene therapy program for rare blood diseases.

More notable recent Abeona Therapeutics Inc. (NASDAQ:ABEO) news were published by: which released: “Abeona Therapeutics (ABEO) Tops Q1 EPS by 1c” on May 11, 2018, also with their article: “Genomic Medicine: Catch The Gene Therapy Wave” published on May 14, 2018, published: “Krystal Biotech: Important Catalyst And Value Inflection Point Approaching” on May 08, 2018. More interesting news about Abeona Therapeutics Inc. (NASDAQ:ABEO) were released by: and their article: “Your Daily Pharma Scoop: Abeona’s ABO-202, Revance Update, Ionis/Biogen’s New Collaboration” published on April 23, 2018 as well as‘s news article titled: “Abeona Therapeutics Announces Upcoming Presentations” with publication date: May 08, 2018.

Abeona Therapeutics Inc. (NASDAQ:ABEO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.